- Previous Close
11.90 - Open
11.95 - Bid 11.00 x --
- Ask 11.45 x --
- Day's Range
10.75 - 11.95 - 52 Week Range
8.90 - 20.20 - Volume
29,934 - Avg. Volume
23,052 - Market Cap (intraday)
573.146M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-2.18 - Earnings Date Feb 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.07
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson's; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
www.irlab.seRecent News: IRLAB-A.ST
View MorePerformance Overview: IRLAB-A.ST
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IRLAB-A.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRLAB-A.ST
View MoreValuation Measures
Market Cap
617.23M
Enterprise Value
587.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.19
Price/Book (mrq)
16.23
Enterprise Value/Revenue
11.60
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-222.69%
Return on Assets (ttm)
-38.55%
Return on Equity (ttm)
-121.20%
Revenue (ttm)
50.62M
Net Income Avi to Common (ttm)
-112.72M
Diluted EPS (ttm)
-2.18
Balance Sheet and Cash Flow
Total Cash (mrq)
90.38M
Total Debt/Equity (mrq)
158.53%
Levered Free Cash Flow (ttm)
-38.96M